ArticleResearch (Washington, D.C.)2026
LXRα/SCD1-Mediated Endoplasmic Reticulum-Mitochondria Crosstalk in Inhibiting Neuronal Ferroptosis after Spinal Cord Injury.
Article in Research (Washington, D.C.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Inter-Organelle Membrane Contact Sites as Physiological Regulatory Hubs in the Brain: From Neurons to Glial Cells.Biomolecules · 2026Review
- LXR Pathway Activation by T0901317: A Novel Potential Experimental Strategy for ALS-Related Cognitive and Motor Impairments via Suppression of Necroptosis-associated RIPK1/RIPK3/MLKL Markers.Molecular neurobiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spinal cord injury (SCI) causes extensive neuronal loss, in which ferroptosis is critically involved. Although lipid transport at endoplasmic reticulum-mitochondria contact sites (ERMCSs) has been implicated in facilitating ferroptosis, the neuron-specific regulatory mechanisms remain elusive. Here, we show that neuronal ferroptosis is characterized by excessive ERMCS formation. Mechanistically, a systematic screening revealed the down-regulation of stearoyl-CoA desaturase 1 (SCD1), a critical enzyme in the synthesis of monounsaturated fatty acids (MUFAs) in neurons, following SCI (in vivo) or erastin treatment (in vitro). We demonstrated that SCD1 deficiency is the driving force behind aberrant ERMCS expansion, leading to increased lipid peroxidation and neuronal ferroptosis. Conversely, SCD1 overexpression could reverse these effects. Furthermore, we identified liver X receptor alpha (LXRα) as a direct transcriptional activator of SCD1. Pharmacological activation of LXRα with T0901317 upregulated SCD1 expression, which in turn restrained ERMCS formation, elevated MUFA levels, and ultimately inhibited neuronal ferroptosis. In murine SCI models, both adeno-associated virus-mediated neuronal SCD1 overexpression and LXRα agonist treatment effectively mitigated excessive ERMCS, reduced lesion size, preserved neuronal architecture, and improved functional recovery. Collectively, our study establishes the LXRα-SCD1 axis as a novel and druggable pathway for reducing neuronal loss and improving functional recovery by modulating ERMCS-dependent lipid exchange dynamics, revealing promising therapeutic targets after central nervous system trauma.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.